OHE has published a new report discussing a framework to help middle-income countries efficiently identify medicines for formulary inclusion. A second publication applies this framework to the Mexican decision making system as a case study.
Just published is a new OHE Consulting Report entitled: Four Case Studies to Explore the Added Value of Oxford AHSN. The report provides evidence that the Oxford AHSN is capable of promoting high quality NHS care and delivering projects which improve patient outcomes, at a cost that appears to represent good value for money.
This post summarises OHE’s activities at this year’s ISPOR Latin America conference in Santiago, September 2015. Topics include policy options for formulary development in middle-income countries, and role of HTA in definition of health benefit plans.
It is estimated that one in three people born in 2015 in the UK may develop dementia, and clinical development success rates for dementia drugs are consistently lower than those for other therapy areas.
A new OHE Consulting Report examines the importance and history of HTA evaluations for additional uses for cancer drugs after their initial approval. The potential value of a new medicine is not likely to be fully known at the time of marketing approval. New uses can expand both the therapeutic and financial value of a particular medicine. In a new study, OHE Consulting seeks to describe and quantify such ‘value expansion’ for a cohort of cancer drugs.